Carlos Fernandez, PharmD

Medical Advisor Nephrology/Cardiovascular Medical Affairs, Novartis Canada. Views, posts, opinions are my own, not that of my employer.

[Heart_BMJ @Heart_BMJ]

https://t.co/D4vwvNZEYe Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era

[Neurotorium @neurotorium]

Approximately 80% of all strokes are ischaemic. The underlying pathology is often multifactorial, involving interrelated arterial and cardiac conditions. Identifying the specific cause of stroke is critical for short-term and long-term care. Learn more: https://t.co/mdNKRmpjJd

[Pablo Corral MD @drpablocorral]

☝️No estimate of the apoB lipoprotein-related risk of CVD is complete without measurement of both apoB and Lp(a)

ApoB is the true core marker of atherogenic particle burden, and Lp(a) is an independent, non-negotiable player in cardiovascular risk.

✅ ApoB reflects the number of atherogenic particles, not just the cholesterol they carry.
✅ Lp(a) adds risk beyond ApoB—even in normolipidemic patients.
✅ The combination of both offers superior prediction of events and treatment guidance.

👉 It's time to stop counting cholesterol and start counting particles.

If your risk assessment doesn’t include ApoB and Lp(a), you’re not seeing the full picture.
Let’s raise the bar in preventive cardiology.

https://t.co/KHo83CXRvU

@society_eas
@fhpatienteurope
@escardio
@ehj_ed

[American College of Cardiology @ACCinTouch]

ICYMI: The ACC recently launched a comprehensive resource package, "HF in a Box," designed to support clinicians in the management of #HeartFailure.

All resources address HF GDMT & are available free of charge in both English & Spanish. Find out more: https://t.co/XCiF6pkP3d

[Prof Derek Connolly @DrDerekConnolly]

This is a very good review of type 2 diabetes

https://t.co/oZZcvGufMW

[Carlos Fernandez, PharmD @rojasfec]

How low can you go…😉

[Pablo Corral MD @drpablocorral]

📢 Hot off the press in @LipidJournal:
LDL-C management just got clearer: “Lower for longer is better.”

This new guidance from the National Lipid Association brings no-nonsense, risk-based recommendations for real-world practice.

✅ LDL-C is causal
✅ Lowering it reduces events
✅ Targets can go <40 mg/dL safely
✅ Time matters—start early, stay low

📉 Don’t wait for plaque to build up—treat the cause, not the consequence.

👉 Read it here: https://t.co/hKP6IQvMTZ

@CBallantyneMD
@nationallipid
@Drlipid

[Carlos Fernandez, PharmD @rojasfec]

@AKECassels @4_doctors It depends on her risk &amp; other clinical factors. Age alone is not enough to determine yes/no. 😉

[Carlos Fernandez, PharmD @rojasfec]

@HeartOTXHeartMD Died too young…

[National Organization for Rare Disorders (NORD) @RareDiseases]

Break down key updates from the @nkf’s 2025 Spring Clinical Meetings—now streaming on @medliveofficial. This free, #CME-credited program offers practical insights into diagnosing and managing two rare forms of #KidneyDisease: C3 glomerulopathy (#C3G) and primary immune complex membranoproliferative glomerulonephritis (#ICMPGN): https://t.co/MAfjaqYWR0

#Nephrology #C3Glomerulopathy #Glomerulopathy #Glomerulonephritis #Kidney #MPGN #MedicalEducation #NKFClinicals @goKDIGO

[Carlos Fernandez, PharmD @rojasfec]

@CMichaelGibson 🤣🤣🤣 a big no!

[Carlos Fernandez, PharmD @rojasfec]

@DrNeilStone It also has MAOI activity …😉

[European Society of Cardiology Journals @ESC_Journals]

SGLT2i can reduce the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. Read more in #EHJ 👉 https://t.co/ITPAx40TVB

@RoccoMontone @ehj_ed #diabetes

[Carlos Fernandez, PharmD @rojasfec]

@DrJacobsRad Great take. I consider these platforms (note I don’t call them AI) to be like a junior assistant.

[NewAmsterdam Pharma Corporation @NewAmsPharma]

@CBallantyneMD’s interest in preventive cardiology was inspired by his family’s history of heart disease. He knows that early interventions—like controlling LDL-C levels—can reduce the burden of cardiovascular disease and save lives. https://t.co/Ui5Ehe5Mko

[Harriette Van Spall, MD MPH 🇨🇦 @hvanspall]

#Betablockers in #HFpEF: no evidence to support use, some evidence of undesirable effects

Do you deprescribe #BBlockers in pts w #HFpEF, particularly given prevalence / burden of #chronotropicIncompetence?

Could there be a role for #pacing HFpEF?

#HFpEFBridgingDisciplines

[𝘈𝘯𝘢𝘦𝘴𝘵𝘩𝘦𝘴𝘪𝘢 @Anaes_Journal]

Central limit theorem

If the sample size is sufficiently large then the sampling distribution of the mean approximates a normal distribution, even if the underlying distribution from which the samples were drawn was not normal.

🔗https://t.co/HB0B67AWvw

[Venk Murthy MD PhD @venkmurthy]

V. interesting paper suggests statins cost effective for essentially all adults

Given this work &amp; recent results from @arjunmanrai @JamesADiao on issues w/ PREVENT vs PCE risk functions, is it time to move beyond risk-centric paradigm for statin allocation?

[Dr Rob 🫀🩺 🇦🇺 @drhungo]

Early intensive lipid lowering therapy saves lives ❤️ 💊 💉

🔸 Strike while the iron is hot (immediately post event)

🔹 Follow patients up & communicate LDL goals to patient & primary care

🔸 Listen to concerns & educate the patient on the ‘legacy affect’ of LDL lowering

LDL⤵️, earlier, longer 👉🏼 better outcomes

@RACGP #MedTwitter #CardioTwitter #MedEd #FOAMed

[Carlos Fernandez, PharmD @rojasfec]

Always love a good review… it’s like my homework is already mostly done ✔️

[Harriette Van Spall, MD MPH 🇨🇦 @hvanspall]

Super review on mineralocorticoid receptor antagonists and the evidence to support their use in #heartfailure across the #LVEF continuum

@AndrewJSauer

https://t.co/kqKd3IJhC0

#MRA #steroidalMRA #nonsteroidalMRA

[Prof Derek Connolly @DrDerekConnolly]

you can reverse heart disease and stabilise plaques